ABBVIE is the best weight player to lose weight

A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.

The booming drug market has won a new potential competitor.

Abbot Said on Monday that will pay up to $ 2.2 billion to develop the experimental drug of obesity of the Danish manufacturer Gubra, marking its late incursion into the segment.

According to the terms of the agreement, the pharmaceutical giant will pay Gubra $ 350 million in advance. ABBVIE will also pay up to almost $ 1.9 billion if the medicine meets certain development and sales milestones.

Gubra, which provides research of preclinical contracts and drug discovery services based on peptides, will be eligible to receive certain royalties on the global net sales of the medication, called GUB014295. Gubra shares closed 15% higher on Monday after the license agreement was announced.

This is important to know about the medicine: it is an injection that mimics amiline, a intestinal hormone different from the existing obesity drugs in the objective of the market.

Amiline activates signals to the brain that suppress appetite and reduce food intake, according to ABBVIE. The hormone also slows the gastric emptying, or the process by which the stomach content moves to the small intestine.

Novo NordiskThe great success treatment imitates the hormone a hormone called LPG-1 to reduce appetite and regulate blood sugar, while Eli LillyZepbound's own medicine addresses both GLP-1 and another hormone called GIP.

Some companies, including Novo Nordisk, Zealand Pharma, Astrazeneca and Structure therapyThey are developing products that go to amiline. Some of these drugs are more advanced in development than Gubra medicine, such as Zealand Petrelintide, but it is still too early to know which is most effective for weight loss.

Some medication manufacturers believe that attacking amiline could reduce gastrointestinal side effects typically observed with treatments that are directed to LPG-1, and can lead to a lower muscle loss than existing medications. But these effects should be tested on clinical trials.

In a research note on Monday, BMO analyst Evan Seigerman said “there we are positive in the agreement” for Abbvie. He said that the company's entry into the obesity market could “come with synergies” to other areas of its business, such as inflammation and aesthetics.

For example, researchers are studying the inflammatory benefits of obesity drugs for conditions as a serious form of liver disease, cardiovascular results and Alzheimer's, among others, wrote Seigerman.

“We see an opportunity for Abbvie to take advantage of his experience in this space to better understand these potential benefits,” he added.

An obesity drug could also complement Abbvie's aesthetic business, which offers Botox, other facial injectables, skin care and body contour, among other products, according to Seigerman.

In particular, the agreement occurs when Abbvie seeks his next best selling drug after the expiration of the patent for his mega box office success Medicine Humira.

“Our Association with Gubra marks our entry into the field of obesity, offering a convincing opportunity based on the potential to address the needs of patients and at the same time promote long -term growth for our company,” said the CEO of Abbvie on Monday, who assumed just over six months ago, in a statement.

However, the agreement could be a “negative potential” for structure therapy, said Seigerman.

This biotechnology company is still looking for possible associations with large pharmaceutical companies to further develop and market its experimental GLP-1 and Amilina products.

Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].

This is Ashley, informing live from Las Vegas, Nevada!

I am here in the field of the Conference and Global Health Exhibition of HIMSS 2025, where medical care and technology leaders are promoting their latest and better innovations. The exhibition floor opens today, but there has already been a lot of ads, mainly around, yes, he guessed it, artificial intelligence.

Here is everything you need to know so far:

• Microsoft On Monday he announced a new assistant of medical care called Dragon Co -nursing that is based on his existing solutions of dictation and environmental listening. It is the company's last impulse to stand out within the markedly competitive market of scribes of AI, which has grown immensely in recent years. Read the CNBC coverage here.
• Amazon On Monday he is taking Amazon One to Nyu Langone Health, which means that patients can register for appointments simply scanning their palm. The service will help Nyu Langone accelerate the login process and relieve administrative workloads. Read the CNBC coverage here.
• Google On Monday, he announced new generative capabilities of AI on its vertex ai Search for Health Care, which allows developers to train, adjust and implement different models and applications of AI. The company said that Gemini 2.0 is now available as one of the models in the offer, and a new characteristic called visual that will allow doctors to look for diagrams, tables and graphics.
• Salesforce On Friday he will launch Agentforce for Health, a set of preconstructed actions and skills that will allow suppliers, payers and others to easily build AI agents. Agentforce for Health specializes in public health, clinical skills and access and services of patients. It occurs after Salesforce announced agentforce, an AI agents service, more widely in September.
• Wolters Kluwer Health announced this week that the company is integrating its updated medical database with the Suki AI AI tool and the medical care agents service at Microsoft Copilot Studio. Ideally, this will facilitate doctors who use these platforms to extract confidence medical resources faster and easier.
• Ge Healthcare On Tuesday he announced a new portfolio of cloud image software solutions called Genesis. The portfolio includes four different offers that will help suppliers to manage and store large amounts of medical images more easily, the company said.

There is still much more to come this week (assuming that I do not lose me completely in the Venetian), so be sure to keep up with the coverage of CNBC. I will have more about the big topics and the conclusions I listen to in the next few days.

Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].